SAN

80.25

-0.16%↓

SAN

80.25

-0.16%↓

SAN

80.25

-0.16%↓

SAN

80.25

-0.16%↓

SAN

80.25

-0.16%↓

Galapagos NV

Затворен

СекторЗдравеопазване

28 -0.85

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.74

Максимум

28.3

Ключови измерители

By Trading Economics

Приходи

-96M

-202M

Продажби

5.9M

71M

Марж на печалбата

-284.019

Служители

704

EBITDA

-190M

Препоръки

By TipRanks

Препоръки

Продай

12-месечна прогноза

-11.46% downside

Дивиденти

By Dow Jones

Следващи печалби

23.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

13M

1.9B

Предишно отваряне

28.85

Предишно затваряне

28

Настроения в новините

By Acuity

37%

63%

103 / 352 Класиране в Healthcare

Galapagos NV Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.02.2026 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Technical Correction -- Market Talk

9.02.2026 г., 23:14 ч. UTC

Пазарно говорене

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9.02.2026 г., 22:29 ч. UTC

Пазарно говорене

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9.02.2026 г., 22:19 ч. UTC

Пазарно говорене

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9.02.2026 г., 22:01 ч. UTC

Печалби

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9.02.2026 г., 21:58 ч. UTC

Печалби

Friedman Industries 3Q Sales $168M >FRD

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 21:48 ч. UTC

Печалби

Friedman Industries 3Q EPS 43c >FRD

9.02.2026 г., 21:17 ч. UTC

Печалби

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9.02.2026 г., 21:13 ч. UTC

Пазарно говорене

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9.02.2026 г., 21:04 ч. UTC

Печалби

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9.02.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9.02.2026 г., 20:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9.02.2026 г., 19:42 ч. UTC

Пазарно говорене

Japan's Yield Curve Expected to Flatten -- Market Talk

9.02.2026 г., 19:31 ч. UTC

Пазарно говорене

Nike Seen Regaining Relevance With Consumers -- Market Talk

9.02.2026 г., 19:27 ч. UTC

Пазарно говорене

Gold Climbs Back Over $5,000/oz -- Market Talk

9.02.2026 г., 19:05 ч. UTC

Пазарно говорене

Nike Returns to List of Hottest Brands -- Market Talk

9.02.2026 г., 18:19 ч. UTC

Пазарно говорене

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9.02.2026 г., 17:41 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9.02.2026 г., 17:31 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 17:17 ч. UTC

Пазарно говорене

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9.02.2026 г., 17:16 ч. UTC

Печалби

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Galapagos NV Прогноза

Ценова цел

By TipRanks

-11.46% надолу

12-месечна прогноза

Среден 24.95 EUR  -11.46%

Висок 27.9 EUR

Нисък 22 EUR

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Galapagos NV през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

0

Купи

1

Задържане

1

Продай

Настроение

By Acuity

103 / 352 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
help-icon Live chat